Cannabis Industry Outlook 2026: $40.5B Sales, $2.3B Tax Break and 6 Stocks to Watch

Legal cannabis sales in North America are forecast to reach approximately $40.5 billion in 2026, with independent analysts projecting annualized growth north of 18% through 2028. Behind the headline number is a sharp divergence: fast-growing new recreational markets are offsetting price compression and oversupply in mature ones, and the entire industry is tilting on whether the Trump administration completes its December 2025 rescheduling directive this year.

This outlook synthesizes the most recent forecasts from Cannabis Business Times, The Armchair Trader, Investing News Network, Cannabis Benchmarks, and Motley Fool, with cross-reference to Q1 2026 sales data and current analyst consensus on the six multistate operators (MSOs) that dominate coverage in 2026.

The Top-Line Numbers

The $40.5 billion forecast for 2026 reflects legal cannabis sales across the United States and Canada, including adult-use and medical markets. The growth drivers break down roughly as follows:

• New adult-use markets maturing — Ohio, New York, Virginia, Minnesota, and Maryland are in various stages of expanding retail footprints and stabilizing supply chains
• Product mix shift — Beverages, edibles, infused pre-rolls, and solventless concentrates are growing faster than flower, with higher margins
• Hemp-derived cannabinoid convergence — Litigation over Delta-8, Delta-9 THC beverages, and other hemp-cannabinoid products is pushing some activity back into state-licensed dispensaries

At the same time, mature markets continue to soften. In California, average item price fell to $18.54 in March 2026, a decline that has accompanied a 9.1% year-over-year drop in overall sales. Oregon average item price fell to $12.19, among the lowest in the country. Outdoor wholesale flower in California is trading around $300 per pound, and an estimated 3 million pounds of unsold cannabis — plus roughly 75,000 pounds of concentrates — remain in Oregon storage. Cannabis Benchmarks forecasts the national average will fluctuate between $1,070 and $1,085 per pound through August 2026.

The $2.3 Billion Rescheduling Math

The most consequential variable in the 2026 outlook is not demand — it is taxes. IRS rule 280E, a legacy of the Controlled Substances Act, bars plant-touching cannabis businesses from deducting ordinary operating expenses (rent, wages, marketing) against federal income tax because cannabis is a Schedule I substance. Effective federal tax rates on cannabis operators frequently exceed 70% of pretax earnings, even when state-level operations are profitable.

Moving cannabis to Schedule III would eliminate 280E immediately. Industry analysts estimate collective annual tax relief of approximately $2.3 billion across the major MSOs, with the largest dollar impacts concentrated at Curaleaf, Green Thumb Industries, Trulieve, and Verano. For context, that single policy change would convert several of the top operators from marginally profitable to meaningfully cash generative on a GAAP basis.

The catch: as of April 17, 2026, the DEA has not published a rescheduling rule. Trump's December 2025 executive directive remains outstanding roughly four months in, and the Attorney General transition following Pam Bondi's removal has created additional uncertainty. Stock prices in the sector reflect that: MSO equities have re-rated modestly off their late-2025 highs but remain above pre-directive levels on the assumption that rescheduling will complete in 2026.

Six Cannabis Stocks to Watch in 2026

The stocks most directly leveraged to the 2026 outlook are a narrow group of multistate operators and one cannabis-adjacent REIT. Because rescheduling timing is binary, each trades like an option on Schedule III.

Green Thumb Industries (OTCQX: GTBIF)

Green Thumb operates dispensaries under the RISE brand in 14 U.S. markets and has one of the strongest balance sheets in the MSO peer set. Analysts point to its disciplined capital deployment, consistently positive operating cash flow, and relatively low leverage as reasons it would benefit quickly from a 280E reversal without the financial distress risk some competitors face. Pennsylvania legalization — if it advances in 2026 — would be a direct catalyst for its existing footprint.

Curaleaf Holdings (OTCQX: CURLF)

Curaleaf is the largest MSO by revenue and the largest 280E payer in absolute terms. Its 280E tax bill has historically exceeded $200 million per year, making it the single biggest dollar beneficiary of rescheduling. Curaleaf has also been the most aggressive acquirer of European cannabis platforms, positioning it for EU-GMP pharmaceutical cannabis exports.

Trulieve Cannabis (OTCQX: TCNNF)

Trulieve dominates Florida's medical cannabis market and is the bellwether for the state's potential adult-use expansion. A successful 2026 Florida legalization vote — though still uncertain — would be transformational. Trulieve has aggressively cut costs and inventory through 2024-2025, and analysts describe its 2026 setup as "operating leverage in a recovery market."

Innovative Industrial Properties (NYSE: IIPR)

IIPR is the only cannabis-focused REIT on a major U.S. exchange. It owns roughly 100 industrial properties leased to licensed cannabis operators. Because it is not plant-touching, IIPR is not subject to 280E, but it gains indirectly: if rescheduling strengthens tenant credit quality, its dividend is safer and any expansion of cannabis real estate demand helps its pipeline.

Cronos Group (NASDAQ: CRON)

Cronos is a Canadian licensed producer with a large cash position from Altria's 2019 investment. Analysts describe it as a "cash-and-optionality" name — its market cap is partially supported by balance sheet alone, and its upside is tied to international expansion and a potential U.S. entry once federal law allows.

Tilray Brands (NASDAQ: TLRY)

Tilray has diversified beyond Canadian cannabis into craft beer, hemp-derived beverages, and European medical cannabis. Its U.S. beverage portfolio gives it a hedge if federal cannabis relaxation is delayed, because hemp-derived THC drinks can be sold in U.S. retail channels without dispensary licensing.

Investors should note all three Canadian operators face ongoing oversupply and pricing pressure in the domestic Canadian market, and all three U.S. MSOs trade on OTC markets with lower liquidity and higher bid-ask spreads than exchange-listed peers.

The Oversupply Question

The biggest downside risk to the 2026 outlook is not regulatory — it is oversupply. Canadian operators have accumulated significant inventory at high production scale, and multiple analyst reports warn that a combination of expanded capacity and flattening demand could push wholesale prices lower still.

In the U.S., mature markets like California, Oregon, Colorado, and Michigan are working through similar dynamics. Colorado cannabis sales have fallen materially from their 2020-2021 peak, and Oregon cannabis sales hit a six-year low in 2025. Price compression forces margin discipline and accelerates industry consolidation — which is why M&A activity is a second major 2026 theme.

Recent deals include Aurora Cannabis's acquisition of Safari Flower for EU-GMP expansion, Verano's smaller bolt-on acquisitions in Pennsylvania and Ohio, and continued Curaleaf consolidation across Europe. Analysts expect more deals in 2026 as stronger balance sheets absorb weaker operators.

Consumer Trends Shaping the Revenue Mix

Within the $40.5 billion top line, product mix continues to shift:

• Pre-rolls and infused pre-rolls are the fastest-growing category, now exceeding 15% of sales in several mature markets
• Beverages are the fastest-growing margin category, benefiting from the hemp-derived THC drink boom
• Solventless hash rosin and other premium concentrates are taking share from shatter and live resin
• Low-dose edibles (2-5 mg) and microdose products are stealing share from 10 mg standard gummies as consumers seek more controlled experiences
• Gummies now account for roughly 72% of edibles sales, cementing format dominance over baked goods and chocolates

The convenience-product trend matters because it is margin-accretive. Pre-rolls, beverages, and small-format edibles carry higher price-per-gram economics than flower.

What to Watch in Q2 and Q3 2026

1. DEA rescheduling action. Any formal DEA publication — proposed rule, hearing schedule, or interim guidance — is the single biggest catalyst.
2. Q1 earnings releases. MSO Q1 reports beginning in May will show how retail sales trends and wholesale pricing are affecting margins.
3. Pennsylvania legalization. If Pennsylvania's budget-tied legalization clears the Senate, it is the largest remaining East Coast adult-use opportunity.
4. Hemp-THC regulatory clarity. The 2026 Farm Bill outcome will determine whether hemp-derived intoxicants remain in state-licensed dispensaries or shift back to the open market.
5. Canadian oversupply data. Aggregate Canadian inventory and wholesale pricing data through Q3 will either confirm or allay oversupply concerns.

Key Takeaways

• Legal cannabis sales are forecast to reach approximately $40.5 billion in 2026 with 18% annualized growth through 2028.
• A DEA move to Schedule III would eliminate IRS rule 280E and deliver an estimated $2.3 billion in annual tax relief across MSOs.
• The six most-watched cannabis equities in 2026 are Green Thumb, Curaleaf, Trulieve, Innovative Industrial Properties, Cronos, and Tilray.
• Mature-market price compression, particularly in California, Oregon, Colorado, and Michigan, is the chief downside risk.
• Pre-rolls, beverages, and low-dose edibles continue to outgrow traditional flower, reshaping margin mix.

Follow cannabis industry news, find dispensaries, and join the community at Budpedia.